





# Impurities Method for Metformin HCL Formulation


## Simple separation of API from melamine and cyanoguanidine



1. Cyanoguanidine



2. Melamine



3. Metformin

**Note:**  $k'$  of cyanoguanidine for this method was found to be over twice that of strong reverse phase methods studied. The reverse phase methods used an ordinary cyano column with an isocratic mobile phase 95% DI H<sub>2</sub>O / 5% acetonitrile. A variety of mobile phase additives were investigated, including 0.1% formic acid, 0.1% TFA, 0.1% TFA + 1 g/L Na octyl sulfate, and 10 mM ammonium acetate. None of the reverse phase methods produced  $k' > 0.3$ .

### Method Conditions

**Column:** Cogent Diamond Hydride™, 4 $\mu$ m, 100Å

**Catalog No.:** 70000-15P-2

**Dimensions:** 2.1 x 150 mm

**Solvents:** A: 50% isopropanol / 50% DI H<sub>2</sub>O / 0.1% acetic acid  
B: Acetonitrile / 0.1% acetic acid

| Gradient: | time (min.) | %B  |
|-----------|-------------|-----|
|           | 0           | 100 |
|           | 2           | 100 |
|           | 5           | 20  |
|           | 9           | 20  |
|           | 10          | 100 |

**Post Time:** 5 min

**Injection vol.:** 1 $\mu$ L

**Flow rate:** 0.4 mL/min

**Detection:** ESI - POS - Agilent 6210 MSD TOF mass spectrometer

**Peaks:** 1. Cyanoguanidine 85.0509 m/z (M+H)<sup>+</sup>  
2. Melamine 127.0727 m/z (M+H)<sup>+</sup>  
3. Metformin 130.1087 m/z (M+H)<sup>+</sup>

### Discussion

A simple method was developed for the analysis of the widely prescribed anti-diabetic drug metformin hydrochloride and for determination of two impurities (cyanoguanidine and melamine) in tablet formulations. This method has the ability to separate metformin from its impurities.

In addition to accurate mass for all three compounds, the peaks were confirmed by injections of standards. The USP-specified impurity limits are not more than 0.02% and 0.01% for cyanoguanidine and melamine respectively.

The precision of this method was evaluated by calculating %RSD of the peak areas of five replicate injections (see Figure B). The obtained value was 0.2%.